Login to Your Account

Clinic Roundup

Thursday, March 21, 2013

• BioMarin Pharmaceutical Inc., of San Rafael, Calif., reported results from a Phase I/II trial, dubbed POM-001, testing BMN-701, a fusion protein of insulin-like growth factor-2 and acid alpha-glucosidase, for late-onset Pompe disease.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription